SGO 2022 Annual Meeting Endometrial Cancer

Here are a few studies on endometrial cancer. Be sure to check my Disparities and Equity research post for those studies related to endometrial cancer. 

Phase 2, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor (ER) Positive Recurrent or Persistent Endometrial Cancer – Konstantinopoulos

 

 

EGFL6 is an Important Growth Factor Involved in Endometrial Cancer Tumorigenesis – A. Garrett

#SGOmtg Dr Garrett : EGFL6 over expressed in endometrial cancer , does it have a role in obesity ( mouse study) ?
EGFL6 Signals MAPK pathway .
EGFL6 Promotes endometrial cancer and may be a target for treatment. #gyncsm

— Dee Sparacio (@womenofteal) March 19, 2022

 

 

 

SIENDO/ENGOT-EN5/GOG-3055: A Randomized Phase 3 trial of Maintenance Selinexor Versus Placebo after Combination Platinum-Based Chemotherapy in Advanced or Recurrent Endometrial Cancer –  Vergote 

Ipatasertib, an Oral AKT Inhibitor, in Combination with Bevacizumab Exhibits Anti-Tumorigenic Effects in Pre-clinical Studies for Endometrioid Endometrial Cancer: Endometrial Cancer Molecularly Targeted Therapy Consortium –  M. Newton

 

In Vivo and In Vitro Efficacy of Enhertu in Uterine Serous Carcinoma – Speaker: L. Mutlu

 

Genomic Alterations, Molecularly Targeted Therapy and Race: Real World Data from the Endometrial Cancer Molecularly Targeted Therapy Consortium – A. Alvarez-Secord

#SGOmtg Dr Secord : ECMT2 study
endometrial cancer incidence and mortality is rising , #gyncsm pic.twitter.com/4WoJd0Cyyw

— Dee Sparacio (@womenofteal) March 20, 2022

 

 

 

 

Thanks for taking the time to read these SGO meeting posts. 

 

Dee

Every Day is a Blessing!